ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity

Phase 1 Completed 25 enrolled Zafgen, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the Pharmacokinetics/Pharmacodynamics (PK/PD), safety, and effectiveness of multiple subcutaneous doses of Beloranib (ZGN-440).

Timeline

Start: 2011-12
Primary completion: 2012-03
Completion: 2012-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Beloranib	Small molecule	—	Subcutaneous

ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity

Summary

Timeline

Drugs

Indications